Carl Hansen is co-founder and CEO of AbCellera, which discovered the world’s first antibody therapy authorized to treat mild to moderate COVID-19. Hansen leads a team of approximately 300 scientists, engineers, data scientists and business professionals in executing more than 100 drug discovery programs. In 2020, AbCellera completed the largest biotech initial public offering in Canadian history.

GREATEST SUCCESS: Being able to attract great people into my life.
FUN FACT: I’m an identical twin.
NON-PROFIT CAUSE: InVision 20/20.
FAVOURITE BOOK: As You Think by James Allen.